ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist that inhibits angiogenesis and growth of liver metastases in a murine model.The combination of ATN-161 plus 5-FU significantly reduces tumor cell proliferation compared to control and single-agent therapy.

RGD peptide (GRGDNP) acts as an inhibitor of integrin-ligand interactions and can induce apoptosis in the absence of signals and integrin-mediated cell clustering.

Bersanlimab (BI-505) is a fully human monoclonal antibody targeting Intercellular Adhesion Molecule-1 (ICAM-1), demonstrating anticancer properties and applicable for studying relapsed/refractory multiple myeloma.